In a phase I multicenter dose escalation study for advanced solid malignancies, in which 36 RCC patients were included and the safety and therapeutic efficacy of the anti-PD 1 antibody MEDI0680 were evaluated, the degree of tumor invasion of CD8+ T cells and the expression of the GZMK gene were also increased after using MEDI0680 (Naing et al. 2019). This evidence concerns the gene CD8A and neoplasm.